文献速递糖尿病

胰岛自身抗体筛查联合或不联合遗传预筛查策略在识别症状前1型糖尿病中的效能

The efficacy of islet autoantibody screening with or without genetic pre-screening strategies for the identification of presymptomatic type 1 diabetes.
PubMed 文献 · Diabetologia · 2025-03-19

本文综述了症状前1型糖尿病筛查策略。在2、6、10岁进行胰岛自身抗体筛查的敏感性可达80%,但参与率和成本是挑战。遗传预筛查可富集高危人群,但存在召回率低、社会经济偏倚和祖先多样性适用性问题。结论认为重复胰岛自身抗体筛查仍是最有效的独立方法,在资源充足且策略公平的前提下,部分场景可先做遗传筛查。

要点

  • 在2、6、10岁进行胰岛自身抗体筛查的敏感性可达80%。
  • 遗传预筛查可识别高危亚群,但面临召回率低、社会经济偏倚和祖先多样性适用性有限的问题。
  • 重复胰岛自身抗体筛查仍是最有效的独立方法,遗传筛查前置在部分场景可能可行。

核心结论

  • 重复胰岛自身抗体筛查仍是最有效的独立方法,在资源充足且策略公平的前提下,部分场景可先做遗传筛查。
  • 筛查项目的最终成功更多取决于公众和医疗提供者的参与度、高参与率以及解决社会经济和人口差异,而非特定策略。

研究设计与样本

  • 本文为综述,围绕症状前1型糖尿病的筛查策略进行论述,未报告系统检索范围。

主要发现

  • 在2、6、10岁进行胰岛自身抗体筛查的敏感性可达80%。
  • 基于家族史、HLA分型或多基因风险评分的广泛遗传选择策略可识别高危亚群,但面临召回率低、社会经济偏倚和祖先多样性适用性有限的问题。
  • 遗传与自身抗体检测联合使用可能提高预测价值,尤其是即时检测遗传学等创新手段。
  • 数字健康基础设施可能在提高召回率和维持随访依从性方面发挥关键作用。

关键数值与推荐

  • 在2、6、10岁进行胰岛自身抗体筛查的敏感性可达80%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 遗传预筛查的实际获益仍不确定。
  • 广泛遗传选择策略面临召回率低、社会经济偏倚和祖先多样性适用性有限的问题。
  • 将遗传检测整合到常规医疗中的成本效益和基础设施要求仍是重大障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Early detection of type 1 diabetes, in its presymptomatic stage, offers significant clinical advantages, including treatment that can delay disease onset. Current screening focuses on identifying islet autoantibody positivity, with proposed optimal testing at ages 2, 6 and 10 years potentially achieving up to 80% sensitivity. However, challenges arise from participation rates and costs associated with multiple screenings. Genetic pre-screening has been suggested as a complementary strategy to target high-risk individuals prior to autoantibody testing, but its real-world benefits remain uncertain. Broad genetic selection strategies, based on family history, HLA typing or polygenic risk scores, can identify subsets of the population at elevated risk. However, these approaches face issues like low recall rates, socioeconomic biases and limited applicability across diverse ancestries. Additionally, the cost-effectiveness and infrastructure requirements of integrating genetic testing into routine healthcare remain significant hurdles. The combined use of genetic and autoantibody testing could improve predictive value, especially with innovations like point-of-care genetic testing. Yet, the ultimate success of any screening programme depends less on specific strategies and more on maximising public and healthcare-provider engagement, ensuring high participation, and addressing socioeconomic and demographic disparities. Digital-health infrastructure may play a crucial role in improving recall rates and maintaining follow-up adherence. In conclusion, while repeated islet autoantibody screening remains the most effective standalone approach, conducting genetic screening prior to islet autoantibody testing may be practical in certain contexts, provided that sufficient resources and equitable strategies are employed. Public engagement and robust infrastructure are essential to realising the full potential of early type 1 diabetes detection programmes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bonifacio E, Coelho R, Ewald DA, et al. The efficacy of islet autoantibody screening with or without genetic pre-screening strategies for the identification of presymptomatic type 1 diabetes. Diabetologia. 2025. PMID: 40105972. doi:10.1007/s00125-025-06408-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。